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Abstract
OBJECTIVE: To investigate the effect of salvianolic
acid A and C component molecules, which are in-
volved in drug compatibility, on inflammatory cyto-
kine expression that affects human chemokine li-
gand 5 (CCL5) and chemokine ligand 10 (CXCL10)
levels in rats with unilateral ureteral obstruction
(UUO).
METHODS: Fifty Sprague Dawley rats were ran-
domly divided into five groups: normal, model, sal-
vianolic acid A, salvianolic acid C and salvianolic ac-
id A and C groups. The normal group was used as
the control, and the other groups of rats had a UUO
model established. The control group had free ac-
cess to food and water, and the other groups re-
ceived the corresponding drugs for 2 weeks. After
the last administration, urine β2-microglobulin (β
2-MG) and N-acetyl-β-D-glucosaminidase (NAG) lev-
els were analyzed. After 24 h, all rats were sacrificed
and the serum was analyzed for creatinine (Cr) and
blood urea nitrogen (BUN) levels. Rat kidneys were
removed, and CCL5 and CXCL10 inflammatory cyto-
kine mRNA expression was measured using re-
al-time fluorescent quantitative reverse transcrip-
tion-polymerase chain reaction (RT-PCR). Kidney fi-
brosis was observed using hematoxylin-eosin (HE)
staining and Masson trichrome staining.
RESULTS: In the salvianolic acid A and salvianolic
acid C treatment groups, serum Cr and urine NAG
levels were significantly lower than in the model
group (both P < 0.05). In all treatment groups, urine
β2-MG levels were significantly lower than in the
model group (all P < 0.05). Compared with model
group, the pathological changes and collagen de-
position improved to varying degrees (both P <
0.05). CCL5 and CXCL10 mRNA expression de-
creased to different degrees compared with the
model group (both P < 0.05).
CONCLUSION: Salvianolic acid A and C are compo-
nent molecules of drug compatibility, and they
may protect renal function and improve tubular
function and renal pathology to a certain degree in
UUO. This improvement may be related to a reduc-
tion in inflammatory cytokines CCL5 and CXCL10
secretion in the UUO rat kidney.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Chronic kidney disease (CKD) is mainly characterized
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by excessive deposition of extracellular matrix and fi-
brosis, causing decreased renal function. Because of its
high morbidity and mortality, CKD has become a
global public health problem. Renal fibrosis, including
glomerulosclerosis and renal interstitial fibrosis (RIF),
caused CKD and end-stage renal disease.1 Related stud-
ies showed that RIF is more important than the glo-
merular lesions in the progression of CKD.2 RIF is an
important part of the clinical exacerbation process in
chronic renal failure, and it is also is one of the main
targets for Chinese medicine in prevention and treat-
ment of CKD. Inflammatory cell infiltration is the ba-
sic pathology of CKD, and it is closely associated with
RIF.3 Inflammation induced by infiltration of inflam-
matory cells can cause tubular epithelial and fibroblast
cells to secrete inflammatory chemokines and cause
progressive tubulointerstitial damage and fibrosis, ulti-
mately leading to end-stage renal disease by activating
the leukocyte-mediated chemokine and chemokine re-
ceptor system. In vitro studies have demonstrated that
fibroblast cells secrete several inflammatory chemo-
kines in the process of renal fibrosis, including Chemo-
kine (C-C Motif) Ligand 2 (CCL2), Chemokine (C-C
Motif) Ligand 3 (CCL3), restructuring human chemo-
kine ligand 5 (CCL5) and chemokine ligand 10 (CX-
CL10).4 Related research has found that inhibiting tu-
bulointerstitial leukocyte recruitment by blockade of
chemokine action may mitigate chronic renal inflam-
mation and subsequent fibrosis.5 Thus, reducing in-
flammatory chemokine secretion may be a new target
for prevention and treatment of renal fibrosis.
Danshen (Radix Salviae Miltiorrhizae) and Traditional
Chinese Medicines containing a salvia decoction are
widely used in the prevention and treatment of renal fi-
brosis.6 A related study on water-soluble active compo-
nents of Danshen (Radix Salviae Miltiorrhizae) demon-
strated that water-soluble active components from
Danshen (Radix Salviae Miltiorrhizae), including salvi-
anolic acid A and C, have strong antioxidant activity
and antithrombotic effect by scavenging oxygen free
radicals and inhibiting lipid peroxidation reaction.7
Kidney collateral stasis is a key pathogenesis of renal fi-
brosis. Therefore, salvianolic acid A and C component
compatibility in renal fibrosis pathogenesis works
through promoting blood circulation and removing
blood stasis, cooling blood and eliminating the role of
carbuncles. In this study, we selected salvianolic acid A
and C in molecular medicine, and we used a UUO ex-
perimental model to study the effect of salvianolic acid
A and C molecule compatibility on the inflammatory
cytokines CCL5 and CXCL10. We established a new
method of molecule drug compatibility in the preven-
tion and treatment of CKD in the experimental study.
MATERIALS ANDMETHODS
Animals
Fifty healthy, specific pathogen-free male Sprague-
Dawley rats, weighing 220-250 g (50-60 days old),
were supplied and fed by the Medical Research Center
of Guangdong Province of China (Certificate of quali-
ty No. SCXK [Yue] 2008-0002).
Modeling and grouping
A total of 50 rats were randomly divided into five
groups using the random number table method, as fol-
lows: control group given saline lavage (n = 10), model
group (n = 10), salvianolic acid A group (n = 10), salvi-
anolic acid C group (n = 10) and salvianolic acid A+C
group (n = 10). The UUO model was established
through unilateral ureteral ligation. Firstly, after anes-
thesing rat and disinfectting the skin, away from the
spine at approximately 1-1.5 cm, peeled subcutaneous
fascia layer by layer and cut muscle to expose the renal
pelvis and ureter. Then separated right ureter and cut it
in the middle. Next, Finally, closed abdominal cavity,
sterile dressing coverd.
Drugs and reagents
Salvianolic acid A and C was purchased from Ze Lang
Pharmaceutical Company (Nanjing, China). Drugs
were configured to the appropriate concentration with
saline, and dosage was 12.50 mg·kg－1·d－1.8 Rat β2-mi-
croglobulin (β2-MG) and N-acetyl-β-D-glucosamini-
dase (NAG) enzyme-linked immunosorbent assay (ELI-
SA) kits were purchased from CUSABIO (Wuhan,
China). The Masson staining kit was purchased from
Jian Cheng Institute of Biotechnology (Nanjing, Chi-
na). Trizol and AMV First Strand cDNA Synthesis Kit
ABI and SybrGreen PCR Master Mix were purchased
from Sangon Biotechnology Company (Shanghai, Chi-
na).
Renal function assay
Twenty-four hours after the last intragastric administra-
tion, the rats in each group were anesthetized and their
abdominal cavity was opened under sterile conditions
to collect blood from the abdominal aorta. Serum was
separated by centrifugation, and serum creatinine (Cr)
and blood urea nitrogen (BUN) were measured using
the enzymatic dynamic method.
Renal tubular function assay
After the last intragastric administration, rats were
placed in metabolic cages to collect urine. Urine β2-MG
and NAG were tested using ELISA kits, according to
the manufacturer's instructions.
Renal pathology observation and score
Half the kidney tissue was fixed in 4% paraformalde-
hyde, dehydrated in ethanol, embedded in paraffin and
sliced to a thickness of approximately 3 μm for routine
hematoxylin-eosin (HE) staining and Masson tri-
chrome staining. Pathological changes in renal tissues
were observed under light microscopy. HE staining of
tubulointerstitial injury were evaluated using semi-quan-
titative scoring according to the Banff criteria:9 (a) no
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tubular dilatation, inflammation, atrophy or necrosis
was scored as 0; (b) mild pathological changes and tu-
bulointerstitial lesions less than 25% was scored as 1
point; (c) moderate pathological changes with tubu-
lointerstitial lesions ranging from 26%-50% was
scored as 2 points; and (d) severe pathology changes
and greater than 50% tubulointerstitial lesions was
scored as 3 points. In each slice, 10 consecutive
non-overlapping high power (× 400) fields were count-
ed, and the average was calculated to compare the ex-
tent of tubulointerstitial injury among the groups. As
described above. The average score of each slice was cal-
culated to compare the degree of RIF among all
groups. Photographs of HE and Masson staining were
taken using an inverted fluorescence microscope
(IX71, Olympus Co., Tokyo, Japan).
Real-time fluorescent quantitative reverse
transcription-polymerase chain reaction microarray
RNA was prepared using Trizol, and its yield and quali-
ty were assessed using UV absorbance and denaturing
agarose gel electrophoresis. First strand cDNA was syn-
thesized by Reverse Transcriptase, and cDNA samples
were diluted and loaded for analysis using 96-well re-
al-time PCR arrays (ABI Co., Carlsbad, CA, USA). All
assays were performed according to the manufacturer's
protocols. β-actin was used as an internal control gene
during the experiment. The real-time amplification
curve and the dissociation curve of each gene were
then obtained. The cycle threshold (Ct) values were ob-
tained, and the 2-ΔΔCt Method10 was used to calculate
the relative expression of target genes (Table 1).
Statistical analysis
All data were analyzed using SPSS 16.0 (SPSS, Chica-
go, IL, USA) software. Quantitative data are expressed
as he mean ± standard deviation ( xˉ ± s). The single
factor analysis of variance for a completely random-
ized design was used to compare parameters among
groups. The least significant difference method and
Tamhane's T2 test were used to compare parameters
between groups. P < 0.05 was considered statistically
significant.
RESULTS
Effect of salvianolic acid A and C compatibility on
renal function
Serum Cr and BUN levels showed that renal function
was significantly damaged in UUO rats compared with
the control group (P < 0.05). In the salvianolic acid A
and salvianolic acid C treatment groups, serum Cr lev-
els were significantly reduced compared with control
group (both P < 0.05), and there was no significant dif-
ference between the other treatment groups and the
model group (P > 0.05). There was no significant dif-
ference in serum BUN levels between any treatment
groups and the model group (P > 0.05; Table 2).
Effect of salvianolic acid A and C compatibility on
renal tubular functionβ2-MG and NAG levels in UUO rats were significant-
ly higher than those in the control group (P < 0.05). In
all treatment groups, β2-MG levels were significantly
lower than the model group (all P < 0.05), and there
were no significant differences among the treatment
groups (all P < 0.05). In the salvianolic acid A and sal-
vianolic acid C groups, NAG levels were significantly
reduced (both P < 0.05), and in the salvianolic acid C
group, the NAG level was significantly lower than the
salvianolic acid A+C group (P < 0.05; Table 3).
Gene
CCL5
CXCL10
β-actin
GenBank access number
NM_031116.3
NM_139089.1
NM_031144.3
Forward primer (5′-3′)
GTGCCAACCCAGAGAAGAAGT
AAAGCGGTGAGCCAAAGAA
CGTAAAGACCTCTATGCCAACA
Reverse primer (5′-3′)
GAGCAAGCAATGACAGGAAAG
GGAGAAACAGGGACAGTTAGGAC
AGCCACCAATCCACACAGAG
Table 1 Gene primer sequences
Notes: CCL5: restructuring human chemokine ligand 5; CXCL10: chemokine ligand 10.
Group
Control
UUO
Salvianolic acid A
Salvianolic acid C
Salvianolic acid A and C
n
7
7
7
7
7
Cr (μmol/L)
28.2±3.0
44.1±16.0a
32.4±6.8b
30.8±7.4b
38.0±7.1
BUN (mmol/L)
7.8±0.5
11.4±1.8a
9.3±0.8a
12.3±2.2a
9.5±1.4
Notes: control group was treated with physiological saline for 2 weeks. UUO group was treated with physiological saline for 2 weeks. Salvi-
anolic acid A group was treated with salvianolic acid A 12.50 mL/kg for 2 weeks. Salvianolic acid C group was treated with salvianolic acid
C 12.50 mL/kg for 2 weeks. Salvianolic acid A and C group was treated with 6.25 mL/kg salvianolic acid A and 6.25 mL/kg salvianolic ac-
id C for 2 weeks. Cr: creatinine; BUN: blood urea nitrogen; UUO: unilateral ureteral obstruction. aP < 0.05, compared with the control
group; bP < 0.05, compared with the UUO group.
Table 2 Effect of salvianolic acid A and C compatibility on serum Cr and BUN levels in UUO rats ( xˉ ± s )
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Effect of salvianolic acid A and C compatibility on
renal pathology
In UUO rats, interstitial tubules were severely dam-
aged and there was significant collagen deposition
compared with the control group (P < 0.05). In all
treatment groups, the pathological changes and colla-
gen deposition improved to varying degrees (all P <
0.05). In the salvianolic acid A group and salvianolic
acid A+C group, the scoring with HE and Masson
staining was lower than the salvianolic acid C group
(both P < 0.05). In the salvianolic acid A+C group,
the scoring with Masson staining was lower than the
salvianolic acid A group (P < 0.05) (Table 4, Figures
1 and 2).
Results of fluorescent quantitative RT-PCR
microarray
Microarray analysis showed that CCL5 and CXCL10
gene expression levels in UUO rats were significantly
higher than that in the control group (P < 0.05). The
treatment groups had varying degrees of reduced ex-
pression compared with the model group (all P <
0.05). In the salvianolic acid A+C group, CCL5 mRNA
expression decreased more significantly than the model
Table 4 Renal pathological evaluation of salvianolic acid A and C compatibility in UUO rat kidney tissue ( xˉ ± s)
Group
Control
UUO
Salvianolic acid A
Salvianolic acid C
Salvianolic acid A and C
n
6
6
6
6
6
HE score
0.05±0.06
2.65±0.10a
1.32±0.18abc
2.35±0.19ab
1.18±0.18abc
Masson score
0.03±0.05
2.65±0.10a
1.72±0.13abc
1.97±0.15ab
1.50±0.13abcd
Notes: control group was treated with physiological saline for 2 weeks. UUO group was treated with physiological saline for 2 weeks. Salvi-
anolic acid A group was treated with salvianolic acid A 12.50 mL/kg for 2 weeks. Salvianolic acid C group was treated with salvianolic ac-
id C 12.50 mL/kg for 2 weeks. Salvianolic acid A and C group was treated with 6.25 mL/kg salvianolic acid A and 6.25 mL/kg salvianolic
acid C for 2 weeks. UUO: unilateral ureteral obstruction. aP < 0.05, compared with the control group; bP < 0.05, compared with the
UUO group; cP < 0.05, compared with salvianolic acid C group; dP < 0.05, compared with salvianolic acid A group.
Figure 1 Pathological changes in the rat kidney in the different groups (HE staining, ×400)
A: Control group; B: UUO group; C: salvianolic acid A group; D: salvianolic acid C group; E: salvianolic acid A and C group. Control
group was treated with physiological saline for 2 weeks. UUO group was treated with physiological saline for 2 weeks. Salvianolic
acid A group was treated with salvianolic acid A 12.50 mL/kg for 2 weeks. Salvianolic acid C group was treated with salvianolic ac-
id C 12.50 mL/kg for 2 weeks. Salvianolic acid A and C group was treated with 6.25 mL/kg salvianolic acid A and 6.25 mL/kg salvi-
anolic acid C for 2 weeks. HE: hematoxylin-eosin; UUO: unilateral ureteral obstruction.
A B C D E
Group
Control
UUO
Salvianolic acid A
Salvianolic acid C
Salvianolic acid A and C
n
6
6
6
6
6
β2-MG
0.167±0.003
0.182±0.005a
0.174±0.006ab
0.176±0.005ab
0.174±0.004ab
NAG
1.137±0.109
2.768±0.516a
2.081±0.482ab
1.667±0.544ab
2.347±0.343ac
Table 3 Effect of salvianolic acid A and C compatibility on β2-MG and NAG in UUO rats (μmol/L, xˉ ± s)
Notes: control group was treated with physiological saline for 2 weeks. UUO group was treated with physiological saline for 2 weeks. Salvi-
anolic acid A group was treated with salvianolic acid A 12.50 mL/kg for 2 weeks. Salvianolic acid C group was treated with salvianolic acid
C 12.50 mL/kg for 2 weeks. Salvianolic acid A and C group was treated with 6.25 mL/kg salvianolic acid A and 6.25 mL/kg salvianolic ac-
id C for 2 weeks. β2-MG: β2-Microglobulin; NAG: N-acetyl-β-D-glucosaminidase; UUO: unilateral ureteral obstruction. aP < 0.05, com-
pared with the control group; bP < 0.05, compared with the UUO group; cP < 0.05, compared with salvianolic acid C group.
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group (P < 0.05). In the salvianolic acid A group and
salvianolic acid A +C group, CXCL10 expression was
lower than the salvianolic acid C group (both P <
0.05). The β-actin amplification curve, CCL5 and CX-
CL10 had a good amplified signal, and the dissociation
curve for each gene had only a single peak, indicating
the specificity of amplification (Table 5).
DISCUSSION
Serum Cr and BUN have been widely used as indica-
tors of renal function. Serum Cr and BUN levels were
significantly elevated in UUO rats compared with the
control rats, confirming that the UUO model of RIF
had been successfully generated. In the salvianolic acid
A and salvianolic acid C treatment groups, serum Cr
levels were significantly decreased compared with the
model group. However, there was no significant
dose-response relationship for the serum BUN levels
between any of the treatment groups and the model
group. This showed that salvianolic acid A and C
could protect renal function in UUO rats.β2-MG is a small-molecule immunoglobulin that is
produced by lymphocytes, platelets and polymorpho-
nuclear leukocytes. It has constant rate of synthesis and
release under normal circumstances, and the content in
normal urine is low. Almost all β2-MG can be free-fil-
tered from the glomerulus, and more than 99% is reab-
sorbed by the proximal tubule, then transported to the
lysosomes and resolved into amino acids. When renal
function is impaired, the glomerular filtration rate is re-
duced and clearing β2-MG is difficult, resulting in in-
creasing urine β2-MG levels, which indicates a reduc-
tion in tubular reabsorption function. Therefore, urineβ2-MG is considered to be a classic marker protein for
tubules that can directly reflect tubular function.11,12
NAG is a 140-KD lysosome that is mostly stored in
the nephron proximal convoluted tubule cells. Its half-
life in plasma is approximately 5 min, and plasma NAG
can't through the glomerulus. The increase in urine
NAG activation suggests that the proximal tubular epi-
thelial cell dysfunction may be a result of renal toxicity,
leading to lysosome rupture and the release NAG.
NAG is an another sensitive early indicator of renal tu-
bular injury.13 Our results showed that urine β2-MG
and NAG levels were significantly increased in UUO
rats compared with normal rats, and β2-MG levels were
significantly decreased in all treatment groups. NAG
levels were significantly reduced in the salvianolic acid
A and salvianolic acid C groups. This indicated that sal-
vianolic acid A and C compatibility could improve re-
nal tubular function to a certain degree inUUO rats.
A B C D E
Figure 2 Pathological changes in the rat kidney in the different groups (Masson staining, ×400)
A: control group; B: UUO group; C: salvianolic acid A group; D: salvianolic acid C group; E: salvianolic acid A and C group. Control
group was treated with physiological saline for 2 weeks. UUO group was treated with physiological saline for 2 weeks. Salvianolic
acid A group was treated with salvianolic acid A 12.50 mL/kg for 2 weeks. Salvianolic acid C group was treated with salvianolic ac-
id C 12.50 mL/kg for 2 weeks. Salvianolic acid A and C group was treated with 6.25 mL/kg salvianolic acid A and 6.25 mL/kg salvi-
anolic acid C for 2 weeks. UUO: unilateral ureteral obstruction.
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Table 5 Effect of salvianolic acid A and C on CCL5 and CXCL10 expression levels in UUO rats ( xˉ ± s )
Group
Control
UUO
Salvianolic Acid A
Salvianolic Acid C
Salvianolic Acid A and C
n
3
3
3
3
3
CCL5
1.51±0.45
11.15±0.80a
6.20±0.43abc
8.12±0.83ab
5.12±0.16abcd
CXCL10
1.10±0.18
6.31±0.97a
2.41±0.56abc
3.67±0.84ab
2.33±0.48abc
Notes: control group was treated with physiological saline for 2 weeks. UUO group was treated with physiological saline for 2 weeks. Salvi-
anolic acid A group was treated with salvianolic acid A 12.50 mL/kg for 2 weeks. Salvianolic acid C group was treated with salvianolic acid
C 12.50 mL/kg for 2 weeks. Salvianolic acid A and C group was treated with 6.25 mL/kg salvianolic acid A and 6.25 mL/kg salvianolic ac-
id C for 2 weeks. CCL5: restructuring human chemokine ligand 5; CXCL10: chemokine ligand 10; UUO: unilateral ureteral obstruction.
Compared with the control group, aP < 0.05; compared with the UUO group, bP < 0.05; compared with salvianolic acid C group, cP <
0.05; compared with salvianolic acid A group, dP < 0.05.
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We found that kidneys in UUO model rats were signif-
icantly larger than those from normal rats, the renal
pelvis and calyces were dilated into cysts that contained
urine, the renal parenchymal showed atrophy and thin-
ning, and the cortex and medulla boundaries were in-
distinct. Under light microscopy, histopathological
changes in the renal tissue indicated that the UUO
model had been successfully established. In all treat-
ment groups, the histopathological changes were signif-
icantly improved compared with the model group. In
the salvianolic acid A group and salvianolic acid A+C
group, HE and Masson scores were lower than in the
salvianolic acid C group. In the salvianolic acid A+C
group, Masson scores were lower than the salvianolic
acid A group. Thus, salvianolic acid A and C compati-
bility could improve renal pathology to a certain de-
gree in UUO rats, and there were some dose-response
effects.
Previous studies showed that renal interstitial inflam-
mation injury is the fundamental cause of fibrosis.14,15
This process is mediated in a paracrine manner because
inflammatory cells can activate fibroblasts and tubular
epithelial cells to secrete pro-fibrotic factors and there-
by promote RIF.16,17 Inflammatory chemokines are
pro-fibrotic factors with a relatively low molecular
weight (8-10 Kd), which are secreted by different types
of cells. They have a chemotaxis effect on various kinds
of leukocyte subclasses such as neutrophils, monocytes
and lymphocytes,18,19 and they are the critical factors
that initiate the renal interstitial inflammatory cascade
reaction.18,20 To date, inflammatory chemokines have
been grouped into four families: CXC, CC, CX3C and
XC. The main families are CXC and CC. These inflam-
matory chemokines bind to the seven transmembrane
G-protein-coupled receptor families; CCL5 belongs to
the CC family, while CXCL10 belongs to the CXC
family.21 Many factors involved in kidney damage can
induce tubular epithelial cells expression of inflamma-
tory chemokines, thereby promoting inflammatory cell
infiltration, and gradually forming RIF that is promot-
ed by interstitial inflammation.22 In this research, we
found that CCL5 levels and CXCL10 gene expression
in UUO rats were significantly greater than in the con-
trol group; the treatment group had a greater different
amount of reduction than the model group. This sug-
gests that the secretion of inflammatory chemokines in-
creased in UUO rats, and that these inflammatory cyto-
kines are involved in the development and progression
of renal fibrosis. We also showed that salvianolic acid A
and C compatibility could interfere with UUO in the
rat kidney through CCL5 and CXCL10 secretion.
In conclusion, our study demonstrated that the effect
of molecule drug compatibility on the renal fibrosis
mechanism had several targets. These findings provide
a scientific rationale for the basis of using salvianolic ac-
id A and C to treat patients with CKD. Further re-
search is necessary to obtain a full understanding of the
appropriate way to modulate renal fibrosis.
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